Table 4.

Dosage of metformin and hazard ratios (HRs) with 95% confidence intervals (CIs) of disease-specific mortality in gastric adenocarcinoma.

Dosagea	Number of deaths	Crude HR (95% CI)	Adjusted HR (95% CI)b
<225 DDD	101	1.00 (Reference)	1.00 (Reference)
225–450 DDD	113	1.06 (0.81–1.38)	1.06 (0.81–1.39)
450–700 DDD	90	0.91 (0.68–1.21)	0.93 (0.69–1.23)
>700 DDD	90	0.91 (0.69–1.21)	0.97 (0.72–1.29)
P for trend		0.338	0.598

^aDefined by total defined daily dose (DDD) used in the two years before the diagnosis of gastric adenocarcinoma.

^bAdjusted for sex, age, calendar year of gastric adenocarcinoma diagnosis, use of non-steroidal anti-inflammatory drugs or aspirin, use of statins, and Charlson Comorbidity Index.